Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P477: Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn’s disease: a tertiary centre real-life experienceECCO '16 Amsterdam

Year: 2016

Authors:

M. Allocca*¹, G. Fiorino¹, C. Bonifacio², A. Spinelli³, A. Repici⁴, A. Malesci^{5, 6}, L. Balzarini², S. Danese^{1, 7}

¹Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, ²Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy, ³Humanitas Research Hospital, IBD Surgery, Colo-rectal Surgery, Rozzano, Milan, Italy, ⁴Humanitas Research Hospital, Endoscopy Unit, Gastroenterology, Rozzano, Milan, Italy, ⁵Humanitas Research Hospital, Gastroenterology, Rozzano, Milan, Italy, ⁶University of Milan, Translational Medicine, Milan, Italy, ⁷Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy

P478: How often high-dose budesonide is necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remissionECCO '16 Amsterdam

Year: 2016

Authors:

F. Fernández-Bañares*¹, M. Piqueras², D. Guagnozzi³, V. Robles⁴, A. Ruiz-Cerulla⁵, M. J. Casanova⁶, J. P. Gisbert⁶, D. Busquets⁷, A. Lucendo⁸, Y. Arguedas⁹, L. Fernández¹⁰

¹Hospital Universitari Mutua Terrassa, Gastroenterology, CIBERehd, Terrassa, Spain, ²Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain, ³Hospital Vall d’Hebron, Gastroenterology, Barcelona, Spain, ⁴Hospital Vall d’Hebron, Department of Gastroenterology, Barcelona, Spain, ⁵Hospital de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Gastroenterology, CIBERehd, Madrid, Spain, ⁷Hospital Universitari Dr Josep Trueta, Department of Gastroenterology, Girona, Spain, ⁸Hospital General De Tomelloso, Department of Gastroenterology, Tomelloso, Spain, ⁹Hospital San Jorge, Gastroenterology, Huesca, Spain, ¹⁰Hospital University Clinic Valladolid, Department of Gastroenterology, Valladolid, Spain

P479: Hepcidin and the risk of malnutrition in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P480: Goals of treatment: preferences of inflammatory bowel disease patientsECCO '16 Amsterdam

Year: 2016

Authors:

F. Casellas*^{1, 2}, C. Herrera de Guise¹, V. Robles¹, E. Navarro¹, N. Borruel¹

¹Hospital Universitari Vall d’Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, ²Hospital Universitari Vall d’Hebron, Barcelona, Spain

P481: Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

F. A. Lucca, C. Malaguti, A. L. Cabalzar, L. A. Chebli, T. C. R. Ribeiro*, P. D. Gaburri, J. M. F. Chebli

Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil

P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitalsECCO '16 Amsterdam

Year: 2016

Authors:

K. H. Song*¹, Y. J. Lee², K. O. Kim³, H. S. Lee⁴, E. S. Kim², J. I. Koo¹, J. S. Jeong¹, W. S. Seo¹

¹Goo Hospital, General Surgery, Daegu, South Korea, ²Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, ³Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, ⁴Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, South Korea

P483: Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

S. Raimundo Fernandes*, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa

Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P484: Access to biologics and biosimilars across 11 European Union countriesECCO '16 Amsterdam

Year: 2016

Authors:

P. Lakatos*¹, E. Domenech², H. Kellner³, J. Marsal⁴, H. Fowler⁵, C. Agboton⁵, N. Georgitseas⁶, M. Cassese⁷, S. Anwar⁶, A. Venugopal⁷, P. Audhya⁵

¹Semmelweis University, Budapest, Hungary, ²Hospital Universitari Germans Trias i Pujol., Badalona, Spain, ³Facharzt für Innere Medizin, Munich, Germany, ⁴Lund University, Lund, Sweden, ⁵Hospira, Warwickshire, United Kingdom, ⁶Navigant, London, United Kingdom, ⁷Navigant, New York, New York, United States

P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

O. Knyazev¹, N. Fadeeva*², A. Kagramanova¹, P. Shcherbakov³, I. Ruchkina¹, A. Parfenov¹, A. Konoplyannikov⁴

¹Moscow Clinical Research Centre, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, ²Moscow Clinical Research Centre, Department of Inflammatory bowel disease, Moscow, Russian Federation, ³Central Research Institute of Gastroenterology, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, ⁴Medical Radiological Scientific Centre, Department of Stem Cells Therapy, Obninsk, Russian Federation

P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

M. Ward*^{1, 2}, L. Beswick², P. Thwaites¹, J. Hogg¹, G. Rosella³, J. Reynolds⁴, D. Van Langenberg², P. Gibson^{1, 3}, M. Sparrow^{1, 3}

¹Alfred Hospital, Gastroenterology, Melbourne, Australia, ²Eastern Health, Gastroenterology, Melbourne, Australia, ³Monash University, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia, ⁴Monash University, Biostatistics, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia

P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisationECCO '16 Amsterdam

Year: 2016

Authors:

W. K. van Deen*¹, M. Skup², A. Centeno¹, N. Duran¹, P. Lacey¹, D. Jatulis³, E. Esrailian¹, M. G. van Oijen⁴, D.W. Hommes¹

¹UCLA Centre for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, California, United States, ²AbbVie, US Immunology, North Chicago, Illinois, United States, ³Anthem Blue Cross, California, Woodland Hills, California, United States, ⁴Academic Medical Centre, Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands

P488: IBS-type symptoms in patients with quiescent inflammatory bowel disease are unrelated to ongoing inflammationECCO '16 Amsterdam

Year: 2016

Authors:

D. Hoekman*¹, J. Zeevenhooven², G. D’Haens³, M. Benninga¹

¹Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, ²Academic Medical Centre (AMC), Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, ³Academic Medical Centre (AMC), Department of Gastroenterology,

P489: Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.ECCO '16 Amsterdam

Year: 2016

Authors:

M. Meglicka*¹, M. Szczepanski², M. Dadalski², J. Kierkus²

¹The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, ²The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P490: Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

B. Jackson*, D. Con, P. De Cruz

Austin Health, Gastroenterology, Melbourne, Australia

P491: In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.ECCO '16 Amsterdam

Year: 2016

Authors:

O. Nomura*, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, S. Watanabe

Juntendo University, Department of Gastroenterology, Tokyo, Japan

P492: Perioperative complications have long-term effect on quality of life after restorative proctocolectomyECCO '16 Amsterdam

Year: 2016

Authors:

Y. Lee¹, A. McCombie*^{1, 2}, R. Vanamala¹, R. Gearry³, F. Frizelle¹, E. McKay¹, J. Williman⁴, T. Eglinton¹

¹University of Otago, Department of Surgery, Christchurch, New Zealand, ²University of Otago, Department of Medicine, Dunedin, New Zealand, ³University of Otago, Department of Medicine, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Department of Population Health, Christchurch, New Zealand

P493: Prevalence and risk factors for postoperative septic complications in Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

M. Guasch^{1, 2}, A. Clos¹, M. Manyosa³, T. Lobatón³, J. R. Gómez², M. Piñol⁴, E. Cabré³, J. Troya⁴, E. Domènech*³

¹Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ²Hospital San Jorge, Digestive Surgery, Huesca, Spain, ³Hospital Germans Trias i Pujol. CIBEREHD, Gastroenterology, Badalona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Digestive Surgery, Badalona, Spain

P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

AOU Careggi, Regional Referral Centre of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

Year: 2016

Authors:

M. Bortlik*^{1, 2}, M. Kolar¹, D. Duricova^{1, 3}, K. Malickova⁴, V. Hruba¹, N. Machkova¹, K. Mitrova¹, M. Lukas¹, M. Lukas^{1, 4}

¹Iscare, IBD Clinical and Research Centre, Prague, Czech Republic, ²First Medical Faculty and Central Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, ³First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, ⁴First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysisECCO '16 Amsterdam

Year: 2016

Authors:

E. J. Louis*¹, R. Löfberg², W. Reinisch³, D. Schwartz⁴, J.-F. Maa⁵, S. Berg⁵, B. Huang⁵, A. W. Wang⁵, A. M. Robinson⁵, B. Pappalardo⁵

¹University of Liège and CHU, Liège, Belgium, ²Karolinska Institutet and IBD Unit, Sophiahemmet, Stockholm, Sweden, ³Medical University of Vienna, Vienna, Austria, ⁴Vanderbilt University Medical Centre, Nashville, United States, ⁵AbbVie Inc., North Chicago, Illinois, United States